Research peptide · LY3298176
Tirzepatide
Simultaneously activates GLP-1 and GIP receptors. In SURMOUNT trials up to 22% body weight loss. FDA-approved as Mounjaro/Zepbound.
Customer Reviews
No reviews yet. Be the first to share your experience.
Research peptide · LY3298176
Simultaneously activates GLP-1 and GIP receptors. In SURMOUNT trials up to 22% body weight loss. FDA-approved as Mounjaro/Zepbound.
No reviews yet. Be the first to share your experience.
/ vial
Independently verified quality
1,250+
satisfied researchers
99.41%
Avg. purity 2026
4.8 ★
Store rating
0.9% benzyl alcohol
€9.99
Tirzepatide (LY3298176) is a 39-amino acid synthetic peptide that functions as a dual agonist at both the GLP-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). This novel mechanism of action, combined with a fatty acid conjugation enabling weekly subcutaneous dosing, has produced some of the most compelling clinical trial data in metabolic research. It is FDA-approved as Mounjaro (T2DM) and Zepbound (obesity).
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.41% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
Tirzepatide is currently available as a 60mg vial. Further dosages will be added shortly.
Tirzepatide acts simultaneously at two receptors: GIP and GLP-1. This dual action distinguishes it from pure GLP-1 agonists like semaglutide.
Store lyophilised powder refrigerated at 2–8°C. After reconstitution, keep refrigerated and use promptly.
>=99% purity, verified by HPLC analysis. Certificate of Analysis included.
Yes, with 2 vials you save €10 per vial, with 3 vials you save €15 per vial compared to individual purchase.
Temperature-controlled cold-chain transport. Free shipping from €250, delivery in 5–9 business days.
Scientific Data
Eli Lilly SURPASS-1 clinical trial
Scientific Data
Scientific Data
Protocol based on: Eli Lilly SURPASS-1 clinical trial
Scientific Data
GLP-1R and GIPR dual agonism: glucose-dependent insulin secretion, appetite suppression via hypothalamic satiety circuits, improved insulin sensitivity in adipose tissue, brown adipose tissue activation via GIPR
Scientific Data
GLP-1 Rezeptor (GLP1R)
Insulin secretion ↑, appetite suppression, gastric emptying ↓
GIP Rezeptor (GIPR)
Insulin potentiation, fat redistribution, bone protection
Scientific Data
Scientific Data
Safety Note
Scientific Data
